Foghorn Therapeutics (FHTX) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Foghorn Therapeutics (FHTX) has outperformed Spruce Biosciences (SPRB) over the past year, losing 52.7% versus a loss of 75.7%. Over five years, FHTX leads with a -83.1% price change compared with -99.8% for SPRB. Spruce Biosciences is the larger company by market cap ($127.6 million vs $124.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | SPRB |
|---|---|---|
| Share price | $2.09 | $44.40 |
| Market cap | $124.12M | $127.61M |
| 1-day change | +6.09% | +3.77% |
| YTD return | -61.30% | -49.03% |
| 1-year return | -52.71% | -75.68% |
| 5-year return | -83.12% | -99.82% |
| Forward P/E | — | 8.92 |
| EPS (TTM) | $-0.98 | $-39.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $199.20 |
| 52-week low | $1.79 | $40.33 |
| Distance from 52-week high | -72.54% | -77.71% |
| Average volume | 617.56K | 77.72K |
| Shares outstanding | 59.39M | 2.87M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FHTX has outperformed SPRB by 23.0 percentage points over the past year.
FHTX vs SPRB FAQ
Which is bigger, Foghorn Therapeutics or Spruce Biosciences?
Spruce Biosciences (SPRB) is larger, with a market capitalization of $127.61M compared with $124.12M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or SPRB?
FHTX returned -52.71% over the past 12 months, compared with -75.68% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.